var title_f10_10_10400="Erythema migrans";
var content_f10_10_10400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema migrans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema migrans with central clearing and a necrotic center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dori F Zaleznik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10400=[""].join("\n");
var outline_f10_10_10400=null;
var title_f10_10_10401="Apical 4 chamber contrast echo LV dysfunction";
var content_f10_10_10401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4-chamber view of an echocardiogram showing contrast-enhanced images in left ventricular dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Successive frames obtained from an apical 4-chamber view of a two dimensional contrast enchanced echocardiogram demonstrates a swirling left ventricular intracavitary contrast flow (pattern B) in a patient with LV dyssynergy and reduced global function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Thanigaraj, S, Chugh, R, Schectman, KB, et al. Am J Cardiol 2000; 85:65, with permission from Excerpta Medica, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10401=[""].join("\n");
var outline_f10_10_10401=null;
var title_f10_10_10402="Left anterior fascicular block";
var content_f10_10_10402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left anterior fascicular block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 136px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An upright QRS complex in lead I and negative QRS complex in aVF is characteristic of a left anterior hemiblock. The QRS duration is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10402=[""].join("\n");
var outline_f10_10_10402=null;
var title_f10_10_10403="EP study tracings BBRVT";
var content_f10_10_10403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study in a patient with bundle branch reentrant ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are five surface ECG leads (I, II, aVF, V1, V6) and intracardiac recordings from the His bundle region (HBE2-3,1-2), the right ventricular apex (RVA3-4), and a mapping catheter (USER1) positioned distal to the His catheter along the RV septum to record a right bundle potential (arrow). The right bundle potential was recorded 30 ms after the His potential (H).",
"    <div class=\"footnotes\">",
"     A: atrial electrogram; V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10403=[""].join("\n");
var outline_f10_10_10403=null;
var title_f10_10_10404="Ferric hexacyanoferrate: Patient drug information";
var content_f10_10_10404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ferric hexacyanoferrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/39/31347?source=see_link\">",
"     see \"Ferric hexacyanoferrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Radiogardase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra cesium or thallium from the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ferric hexacyanoferrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         To avoid exposing or re-exposing others:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use the toilet instead of a urinal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flush the toilet a few times after using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean up any spilled urine, feces, or blood right away. Avoid touching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands after using the toilet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash exposed clothing, bedding, and bath towels alone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid children's urine or feces.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of stool to blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of mouth to blue.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Capsules may be opened and contents mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11261 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10404=[""].join("\n");
var outline_f10_10_10404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216875\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024987\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024986\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024991\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024992\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024994\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024989\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024990\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024995\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024996\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/39/31347?source=related_link\">",
"      Ferric hexacyanoferrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_10_10405="Radiographic views for acetabular fractures";
var content_f10_10_10405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Radiographic views for acetabular fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image depicts the normal lines and relationships of the acetabulum on different radiographic views and schematic pictures.",
"    <br>",
"     (A) Anteroposterior (AP) radiograph of the pelvis. 1, Iliopectineal line; 2, ilioischial line; 3, teardrop; 4, acetabular roof; 5, anterior rim of the acetabulum; 6, posterior rim of the acetabulum. The iliopectineal line, the anterior rim, and teardrop are landmarks of the anterior column; the ilioischial line and posterior rim are landmarks of the posterior columns.",
"     <br>",
"      (B) Iliac oblique radiograph of the pelvis. 1, Posterior border of the innominate bone. 2, Anterior rim of the acetabulum, which is seen best on this view. The iliac wing is seen en face, and fracture lines extending into the iliac wing are often best seen on this view. The proper amount of rotation is indicated by the tip of the coccyx lying just above the center of the contralateral femoral head.",
"      <br>",
"       (C) Obturator oblique radiograph of the pelvis. 1, Iliopectineal line. 2, Posterior rim of the acetabulum. The obturator ring is seen en face, and posterior wall fractures are seen best on this view. The proper amount of rotation is indicated by the tip of the coccyx lying just above the center of the ipsilateral femoral head.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10405=[""].join("\n");
var outline_f10_10_10405=null;
var title_f10_10_10406="Amebic liver abscess";
var content_f10_10_10406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amebic liver abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 37-year-old man with amebic liver abscess.",
"    <br>",
"     (A) Sonogram shows a round mass consisting of a band of peripheral solid part (arrows), and central liquefied part showing low-level internal echoes.",
"     <br>",
"      (B) Contrast-enhanced CT scan shows a peripheral solid part and central liquefied part. At surgery, the central portion was liquefied and contained \"anchovy paste\".",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Park MS, Kim KW, Ha HK, Lee DH. Intestinal parasitic infection. Abdom Imaging 2008; 33:166, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2008.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10406=[""].join("\n");
var outline_f10_10_10406=null;
var title_f10_10_10407="Uveitis: Treatment";
var content_f10_10_10407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uveitis: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10407/contributors\">",
"     James T Rosenbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10407/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/10/10407/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraocular inflammation (ie, uveitis) results from many causes. The approach to therapy depends upon the etiology, location, and severity of the inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/1\">",
"     1",
"    </a>",
"    ]. The management of a patient with uveitis will require consultation with an ophthalmologist or other specialist in uveal eye disease. Ideally, therapy should be initiated within 24 hours of the onset of acute, anterior uveitis, and infectious causes of uveitis should be treated promptly.",
"   </p>",
"   <p>",
"    This topic will focus primarily on the treatment of uveitis that is not related to an active infection. A general approach to evaluation and treatment of the patient presenting with a painful red eye is discussed separately. Treatment of uveitis that is due to infection is discussed in more detail in topic reviews that address management of the specific infection. The etiology, clinical manifestations, and diagnostic approach to a patient with uveitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uvea is the middle portion of the eye. The anterior portion of the uvea includes the iris and ciliary body. The pars plana is the tissue just posterior to the ciliary body and just anterior to the retina. The posterior portion of the uvea is known as the choroid (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation of the anterior uveal tract is called anterior uveitis and is synonymous with iritis. When the adjacent ciliary body is also inflamed, the process is known as iridocyclitis.",
"     </li>",
"     <li>",
"      Terms used to describe uveitis posterior to the lens include vitritis, intermediate uveitis, pars planitis, choroiditis, retinitis, chorioretinitis, or retinochoroiditis. Panuveitis refers to inflammation in the anterior chamber, vitreous humor, and choroid or retina simultaneously. The presence of inflammatory cells in the vitreous humor posterior to the lens is termed intermediate uveitis, even though the vitreous humor is not technically part of the uveal tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UVEITIS DUE TO INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious causes of uveitis are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef61247 \" href=\"UTD.htm?5/40/5773\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral infections may cause either anterior or posterior uveitis. The most common viruses causing uveitis are cytomegalovirus (CMV), herpes zoster, and herpes simplex. These infections should be treated promptly with appropriate antiviral agents. CMV is being increasingly recognized in Asian populations as a cause of a chronic, unilateral anterior uveitis associated with elevated intraocular pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/2\">",
"       2",
"      </a>",
"      ]. Fuchs heterochromic iridocyclitis, a form of chronic unilateral, primarily anterior uveitis, is now considered to be most often secondary to a remote infection with rubella [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/3\">",
"       3",
"      </a>",
"      ]. In herpetic infection of the retina, retinal destruction (acute retinal necrosis) may otherwise progress rapidly. Although immunosuppressed patients are at greater risk for acute retinal necrosis, it may also occur on occasion in patients with an intact immune system.",
"      <br/>",
"      <br/>",
"      CMV retinitis is seen only rarely in immunocompetent patients, while herpes simplex and herpes zoster may affect both immunocompetent and immunocompromised patients.",
"     </li>",
"     <li>",
"      In addition to treating the underlying infection, patients with anterior uveitis due to an infection are often treated with topical glucocorticoids after initiation of antiviral medication. Treatment of ocular involvement due to these viral infections is discussed in the appropriate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link\">",
"       \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of herpes zoster in the immunocompetent host\", section on 'Herpes zoster ophthalmicus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=see_link\">",
"       \"Herpes simplex keratitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of chorioretinitis due to Toxoplasmosis gondii in patients with HIV infection and in immunocompetent adults is discussed separately. Higher doses and longer duration of treatment are generally used in patients with HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link&amp;anchor=H10#H10\">",
"       \"Toxoplasmosis in HIV-infected patients\", section on 'Chorioretinitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"       \"Toxoplasmosis in immunocompetent hosts\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatable infectious causes of uveitis in the immunocompetent host include syphilis, and, less commonly, cat scratch fever, tuberculosis, leprosy, and Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS UVEITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treating noninfectious uveitis varies depending upon the location of the inflammation. There are limited available data from controlled trials. The following recommendations are generally consistent with the approach advocated by a consensus panel of both ophthalmologists and rheumatologists that convened in 2000, prior to any extensive testing of biologic therapies, such as TNF inhibitors, for uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious causes of anterior uveitis are generally treated with topical glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    acetate (1 percent). The frequency for the drops depends upon the intensity of the inflammation. A dilating drop such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    (0.25 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"     cyclopentolate",
"    </a>",
"    (1 percent) can relieve pain due to spasm of the muscles controlling the pupil and will also help to prevent the formation of posterior synechiae that may interfere with the function of the pupil.",
"   </p>",
"   <p>",
"    Uveitis that is primarily posterior to the lens is generally not responsive to topical medication. Options for initial treatment of intermediate or posterior uveitis, or of panuveitis, include observation only or treatment with periocular injection of a glucocorticoid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    (subconjunctival, subtenon, or peribulbar). Intraocular injection of glucocorticoids entails more risk than a periocular injection, but this approach can also provide more potent and more sustained benefit. Some patients, however, may decline a periocular or intraocular injection. The United States Food and Drug Administration (FDA) has approved two glucocorticoids for intraocular injection, a formulation of triamcinolone and a polymer that slowly releases",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Systemic treatment is generally reserved for resistant inflammation and may be indicated in patients with glaucoma who cannot be treated with local injection. In addition, patients with bilateral disease are often treated with systemic therapy. Some specific forms of inflammation such as Beh&ccedil;et's disease or serpiginous choroiditis are more likely to require systemic therapy. The approach to therapy is generally not affected by the etiology of the uveitis, but there are important exceptions. As examples, Beh&ccedil;et's disease is especially responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]; Vogt-Koyanagi-Harada disease may benefit from intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    when the illness first begins; and pars planitis is often managed just by observation or periocular glucocorticoid injections to treat the complication of macular edema, although a preliminary report from Germany suggests that beta interferon might be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disease resistant to initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose anterior uveitis is not controlled with topical glucocorticoids and patients with ongoing posterior inflammation may require systemic glucocorticoid therapy or additional antiinflammatory or immunosuppressive agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids are generally reserved for patients with bilateral disease that has not responded to topical medications and that is interfering with the activities of daily living. A risk-benefit ratio must be considered for any therapeutic decision. Some patients function well with a visual acuity of",
"    <span class=\"nowrap\">",
"     20/70,",
"    </span>",
"    while others are functionally impaired with a visual acuity of",
"    <span class=\"nowrap\">",
"     20/25.",
"    </span>",
"   </p>",
"   <p>",
"    Toxicity",
"    related to oral glucocorticoid use may limit acceptance by patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of glucocorticoid therapy is not to cure but to limit the inflammation. Many forms of uveitis that are severe enough to warrant oral glucocorticoid or other immunosuppressive drugs are chronic, such as sarcoidosis. Thus, the clinician should strive to use the lowest dose of medication that provides acceptable benefit. The dose of oral glucocorticoid varies based on the underlying disease, the disease severity, the patient profile, and the clinician and patient preference. A common initial dose is the equivalent of 40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day, with gradual tapering after response to the lowest dose that controls inflammation.",
"   </p>",
"   <p>",
"    If remission has been achieved for 6 to 12 months, the maintenance dose of glucocorticoid may be gradually discontinued. A shorter course of therapy is usually sufficient in patients with severe iritis associated with the HLA-B27 spectrum of spondyloarthritis. It is rarely necessary to treat such patients with oral therapy for more than two weeks because the eye inflammation generally remits spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antimetabolites or cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of patients with uveitis may require immunosuppressive medications. Indications for their use include bilateral disease, active inflammation, failure to respond to oral glucocorticoid therapy, or severe disease that interferes with activities of daily living. Additionally, patients who require a daily dose of 10 mg or more of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to control their ocular inflammation may benefit from a glucocorticoid-sparing agent, such as an antimetabolite, as a safer long-term alternative. This recommendation is consistent with the consensus of a group of international experts on uveitis management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunosuppressive agents that may be employed include antimetabolites, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/12\">",
"     12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/13\">",
"     13",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/14\">",
"     14",
"    </a>",
"    ]; calcineurin inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ; or alkylating agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . These medications should be used with appropriate caution and careful monitoring. There should be no specific contraindication to the therapy, such as active liver disease when using methotrexate, or hypertension or renal disease when using cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anti-tumor necrosis factor-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of tumor necrosis factor-alpha (TNF) inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in the management of patients with uveitis is uncertain. Further data from controlled trials are needed to clarify the indications and risks of TNF inhibition in the treatment of ocular inflammatory disease. The following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small observational study for children with juvenile idiopathic arthritis and uveitis resistant to initial therapy found that 10 of 16 eyes showed decreased inflammation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/15\">",
"       15",
"      </a>",
"      ], but data from controlled trials have been less positive [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The response of uveitis associated with Beh&ccedil;et's disease to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      has been encouraging in observational studies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/5-8,17-19\">",
"       5-8,17-19",
"      </a>",
"      ]. For example, in an open label observational study of 43 patients, 33 patients responded to conventional therapy (oral glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/8\">",
"       8",
"      </a>",
"      ]. Ten patients who failed to respond were subsequently treated with infliximab (5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      every two weeks for a total of six doses. Patients treated with infliximab had fewer relapses and longer remissions than patients who were treated conventionally. Infliximab has been approved in Japan to treat Beh&ccedil;et's disease, which is a relatively common cause of uveitis in that country.",
"     </li>",
"     <li>",
"      Several reports suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      may be more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      for the treatment of uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. An unusual increase in adverse effects, including drug-induced lupus, was reported in one prospective study using infliximab [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The published experience describing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      in the treatment with uveitis is limited; 16 of 18 children with arthritis and uveitis had improvement in uveitis symptoms with adalimumab treatment in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/23\">",
"       23",
"      </a>",
"      ]. Another nonrandomized study in 33 children with noninfectious chronic uveitis found that adalimumab was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      in achieving remission after 40 months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/24\">",
"       24",
"      </a>",
"      ]. Randomized trials to assess the role of adalimumab in the treatment of uveitis are in progress.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      appeared to reduce the risk of developing eye inflammation in patients with ankylosing spondylitis, a disease frequently associated with acute anterior uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intraocular glucocorticoid releasing implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2005, the FDA approved an intraocular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    implant for patients with refractory posterior uveitis. The surgically implanted device delivers a glucocorticoid into the vitreous humor continuously for about 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataract and glaucoma are common complications, but the implant does not cause systemic toxicity and can be effective in selected patients. An appropriate candidate is an individual with unilateral disease, no systemic illness requiring immunosuppression, and disease that would otherwise require frequent local glucocorticoid injections.",
"   </p>",
"   <p>",
"    The implant carries a slight risk of surgical complications, including endophthalmitis. Almost all patients who have not had prior cataract surgery will develop a cataract, and about 30 percent of patients will require additional surgery for glaucoma. The safety of multiple implantations and continuous steroid exposure beyond 2.5 years is not known.",
"   </p>",
"   <p>",
"    At present, we reserve use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    implant for patients whose noninfectious posterior or intermediate uveitis does not respond adequately to local glucocorticoid injection and in whom systemic use of glucocorticoids or other immune modulators may be particularly problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing clinical trials include the evaluation of an antibody to interleukin-1 beta (gevokizumab), an antibody to tumor necrosis factor-alpha (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ), a calcineurin antagonist (voclosporin), and an intravitreally injected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    to treat refractory intermediate or posterior uveitis.",
"   </p>",
"   <p>",
"    Alpha interferon is used, primarily in Europe, for refractory posterior uveitis or Beh&ccedil;et's disease, if the response to other agents is inadequate. It has also been used to treat persistent cystoid macular edema, a common complication of uveitis that can limit visual acuity. Cystoid macular edema usually responds to control of the underlying inflammation or to the local injection of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/27\">",
"     27",
"    </a>",
"    ]. Alpha interferon requires frequent injections and its use is associated with flu-like symptoms and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\", section on 'Posterior uveitis and other major disease manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention of recurrent episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    can help prevent attacks of HLA B27-associated iritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10407/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This prophylactic approach is appropriate for patients whose attacks are especially frequent or severe. TNF inhibitors are highly effective in reducing the frequency of HLA B27-associated iritis, but the risk and cost usually do not justify their use if the purpose is solely to prevent iritis. Some evidence also indicates that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or oral nonsteroidal antiinflammatory drugs could reduce the frequency of iritis attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=see_link\">",
"       \"Patient information: Uveitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=see_link\">",
"       \"Patient information: Chorioretinitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal management of a patient with uveitis will require consultation with an ophthalmologist or other specialist in eye disease. Ideally, therapy should be initiated within 24 hours of the onset of acute, anterior uveitis, and most infectious causes of uveitis should be treated promptly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of uveitis due to an infectious agent is directed toward the responsible organism. Infection with herpes simplex or herpes zoster may cause retinal destruction (acute retinal necrosis). Antiviral therapy is especially important in the setting of retinitis in order to limit retinal damage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uveitis due to infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uveitis is generally classified as anterior, intermediate, or posterior or as panuveitis (involving all anatomic segments of the uveal tract). Anterior uveitis not due to infection is treated with topical glucocorticoids. Dilating ophthalmic drops are indicated if ciliary spasm is causing pain or if there is risk for posterior synechiae. Posterior or intermediate uveitis and panuveitis are generally not responsive to topical treatment. Initial management of uveitis posterior to the lens is usually by observation or by periocular and occasionally intraocular glucocorticoid injections. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral glucocorticoids are frequently recommended for patients with uveitis that is resistant to topical therapy. Other immunomodulatory agents are suggested in patients who have active inflammation that interferes with activities of daily living and who have one of the following indications (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease resistant to initial treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Refractory uveitis",
"     </li>",
"     <li>",
"      Drug-related adverse effects from systemic glucocorticoids or persistent requirement for a dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      greater than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or equivalent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intraocular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"       fluocinolone",
"      </a>",
"      -releasing implant offers an alternative to systemic therapy, but it may necessitate multiple surgeries for its complications (cataract and glaucoma) and has unknown long-term safety. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Intraocular glucocorticoid releasing implant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/1\">",
"      Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum 2002; 46:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/2\">",
"      Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol 2010; 94:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/3\">",
"      Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol 2004; 138:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/4\">",
"      Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/5\">",
"      Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Beh&ccedil;et's disease. Lancet 2001; 358:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/6\">",
"      Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh&ccedil;et's disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/7\">",
"      Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh&ccedil;et's disease: an open-label trial. Arthritis Rheum 2005; 52:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/8\">",
"      Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh&ccedil;et disease. Am J Ophthalmol 2008; 146:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/9\">",
"      Rosenbaum JT. Future for biological therapy for uveitis. Curr Opin Ophthalmol 2010; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     Mackensen F, Springer C, Wimer P, et al. Long-term results of a monocentric randomized controlled clinical trial comparing interferon beta to methotrexate in the treatment of uveitis macular edema. Invest Ophthalmol Vis Sci 2010; 51:E abstract 2916.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/11\">",
"      Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/12\">",
"      Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009; 148:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/13\">",
"      Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010; 149:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/14\">",
"      Ali A, Rosenbaum JT. Use of methotrexate in patients with uveitis. Clin Exp Rheumatol 2010; 28:S145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/15\">",
"      Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/16\">",
"      Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/17\">",
"      Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/18\">",
"      Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/19\">",
"      Bodaghi B, Bui Quoc E, Wechsler B, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005; 64:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/20\">",
"      Foeldvari I, Nielsen S, K&uuml;mmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/21\">",
"      Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/22\">",
"      Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/23\">",
"      Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/24\">",
"      Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011; 63:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/25\">",
"      Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/26\">",
"      Fluocinolone acetonide ophthalmic--Bausch &amp; Lomb: fluocinolone acetonide Envision TD implant. Drugs R D 2005; 6:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/27\">",
"      Deuter CM, K&ouml;tter I, G&uuml;naydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009; 93:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/28\">",
"      Mu&ntilde;oz-Fern&aacute;ndez S, Hidalgo V, Fern&aacute;ndez-Mel&oacute;n J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003; 30:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10407/abstract/29\">",
"      Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Ba&ntilde;ares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 2000; 14 ( Pt 3A):340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5592 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10407=[""].join("\n");
var outline_f10_10_10407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UVEITIS DUE TO INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONINFECTIOUS UVEITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disease resistant to initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antimetabolites or cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anti-tumor necrosis factor-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intraocular glucocorticoid releasing implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention of recurrent episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5592|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5773\" title=\"table 1\">",
"      Infectious causes of uveitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=related_link\">",
"      Patient information: Chorioretinitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=related_link\">",
"      Patient information: Uveitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_10_10408="Busulfan: Drug information";
var content_f10_10_10408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Busulfan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/32/36357?source=see_link\">",
"    see \"Busulfan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7479?source=see_link\">",
"    see \"Busulfan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with prophylactic anticonvulsant therapy (eg, phenytoin) prior to high-dose busulfan treatment. Prophylactic antiemetics may be necessary for high-dose (HSCT) regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic myelogenous leukemia (CML), palliation (manufacturer&rsquo;s labeling):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remission induction: 60 mcg/kg/day or 1.8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; usual range: 4-8 mg/day; titrate dose (or withhold) to maintain leukocyte counts &ge;15,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (doses &gt;4 mg/day should be reserved for patients with the most compelling symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: When leukocyte count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume induction dose",
"     <b>",
"      or",
"     </b>",
"     (if remission &lt;3 months) 1-3 mg/day (to control hematologic status and prevent relapse)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell (HSCT) conditioning regimen:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.8 mg/kg every 6 hours for 4 days (a total of 16 doses);",
"     <b>",
"      Note:",
"     </b>",
"     Use ideal body weight or actual body weight, (whichever is lower) for dosing. For obese or severely-obese patients, use of an adjusted body weight [IBW + 0.25 x (actual &ndash; IBW)] is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reduced intensity conditioning regimen (unlabeled dosing): 0.8 mg/kg/day for 4 days starting 5 days prior to transplant (in combinations with fludarabine) (Ho, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (unlabeled use):",
"     </i>",
"     1 mg/kg/dose every 6 hours for 16 doses (in combination with cyclophosphamide) (Soci&eacute;, 2001)",
"     <b>",
"      or",
"     </b>",
"     1 mg/kg/dose every 6 hours for 16 doses beginning 9 days prior to transplant (in combination with cyclophosphamide) (Cassileth, 1993)",
"     <b>",
"      or",
"     </b>",
"     0.44 mg/kg/dose every 6 hours for 16 doses (in combination with cyclophosphamide) (Anderson, 1996)",
"     <b>",
"      or",
"     </b>",
"     1 mg/kg/dose every 6 hours for 16 doses beginning 6 days prior to transplant (in combination with melphalan) (Fermand, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Polycythemia vera and essential thrombocythemia (unlabeled uses):",
"     </b>",
"     Oral: 2-4 mg/day (Fabris, 2009; Tefferi, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7479?source=see_link\">",
"      see \"Busulfan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with prophylactic anticonvulsant therapy (eg, phenytoin) prior to high-dose busulfan treatment. Prophylactic antiemetics may be necessary for high-dose (HSCT) regimens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic myelogenous leukemia (CML), palliation (manufacturer&rsquo;s labeling):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remission induction: 60 mcg/kg/day or 1.8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; titrate dose (or withhold) to maintain leukocyte counts &ge;15,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (doses &gt;4 mg/day should be reserved for patients with the most compelling symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: When leukocyte count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume induction dose",
"     <b>",
"      or",
"     </b>",
"     (if remission &lt;3 months) 1-3 mg/day (to control hematologic status and prevent relapse)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell transplant (HSCT) conditioning regimen:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;12 kg: 1.1 mg/kg/dose (actual body weight) every 6 hours for 16 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;12 kg: 0.8 mg/kg/dose (actual body weight) every 6 hours for 16 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjust dose to desired AUC (1125 micromolar&bull;minute) using the following formula:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose (mg) = Actual dose (mg) x [target AUC (micromolar&bull;minute) / actual AUC (micromolar&bull;minute)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Reduced intensity conditioning regimen (unlabeled dosing): 0.8 mg/kg/dose for 1 dose 7-10 days prior to transplant, followed by ~0.8 mg/kg/dose (busulfan kinetics calculated after initial dose) every 6 hours for 7 doses beginning 3-6 days prior to transplant (in combination with fludarabine and antithymocyte globulin) (Pulsipher, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (unlabeled use):",
"     </i>",
"     1 mg/kg/dose every 6 hours for 16 doses beginning 9 days prior to transplant (in combination with cyclophosphamide) (Cassileth, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (refer to individual protocols): Start with lowest recommended doses for adults.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5526939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.V.: No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral: No dosage adjustment provided in the manufacturer&rsquo;s labeling (elimination appears to be independent of renal function); however, some clinicians suggest adjustment is not necessary (Aronoff, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5526940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Busulfex&reg;: 6 mg/mL (10 mL) [contains N,N-dimethylacetamide (DMA), polyethylene glycol 400]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myleran&reg;: 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F143370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravenous busulfan should be infused over 2 hours via central line. Flush line before and after each infusion with 5 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Do not use polycarbonate syringes or filters for preparation or administration",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      HSCT only:",
"     </b>",
"     To facilitate ingestion of high oral doses, may insert multiple tablets into gelatin capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F143441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Palliative treatment of chronic myelogenous leukemia (CML) (oral); conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation (I.V.) for CML",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F143431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conditioning regimen prior to hematopoietic stem cell transplant (HSCT) (oral); treatment of polycythemia vera and essential thrombocytosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Myleran&reg; may be confused with Alkeran&reg;, Leukeran&reg;, melphalan, Mylicon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (44%), hypertension (36%; grades 3/4: 7%), edema (28% to 79%), thrombosis (33%), chest pain (26%), vasodilation (25%), hypotension (11%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Insomnia (84%), fever (80%), anxiety (72% to 75%), headache (69%), chills (46%), pain (44%), dizziness (30%), depression (23%), confusion (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (57%), pruritus (28%), alopecia (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia (77%), hyperglycemia (66% to 67%; grades 3/4: 15%), hypokalemia (64%), hypocalcemia (49%), hypophosphatemia (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (43% to 100%), nausea (83% to 98%), mucositis/stomatitis (79% to 97%; grades 3/4: 26%), anorexia (85%), diarrhea (84%; grades 3/4: 5%), abdominal pain (72%), dyspepsia (44%), constipation (38%), xerostomia (26%), rectal disorder (25%), abdominal fullness (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic:  Myelosuppression (&le;100%), neutropenia (100%; onset: 4 days; median recovery: 13 days [with G-CSF support]), thrombocytopenia (98%; median onset: 5-6 days), lymphopenia (children: 79%), anemia (69%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (49%; grades 3/4: 30%), ALT increased (31%; grades 3/4: 7%), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease) (adults: 8% to 12%; children: 21%), alkaline phosphatase increased (15%), jaundice (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site inflammation (25%), injection site pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (51%), back pain (23%), myalgia (16%), arthralgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine increased (21%), oliguria (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Rhinitis (44%), lung disorder (34%), cough (28%), epistaxis (25%), dyspnea (25%), pneumonia (children: 21%), hiccup (18%), pharyngitis (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection (51%; includes severe bacterial, viral [CMV], and fungal infections), allergic reaction (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (5%), cardiomegaly (5%), atrial fibrillation (2%), ECG abnormal (2%), heart block (2%), heart failure (grade 3/4: 2%), pericardial effusion (2%), tamponade (children with thalassemia: 2%), ventricular extrasystoles (2%), hypervolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Lethargy (7%), hallucination (5%), agitation (2%), delirium (2%), encephalopathy (2%), seizure (2%), somnolence (2%), cerebral hemorrhage (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Vesicular rash (10%), vesiculobullous rash (10%), skin discoloration (8%), maculopapular rash (8%), acne (7%), exfoliative dermatitis (5%), erythema nodosum (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Ileus (8%), weight gain (8%), esophagitis (grade 3: 2%), hematemesis (2%), pancreatitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Prothrombin time increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hepatomegaly (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Hematuria (8%), dysuria (7%), hemorrhagic cystitis (grade 3/4: 7%), BUN increased (3%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Asthma (8%), alveolar hemorrhage (5%), hyperventilation (5%), hemoptysis (3%), pleural effusion (3%), sinusitis (3%), atelectasis (2%), hypoxia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation of skin (5% to 10%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, ovarian suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (anemia, leukopenia, thrombocytopenia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      I.V. and/or Oral:",
"     </b>",
"     Infrequent, postmarketing, and/or case reports: Acute leukemias, adrenal insufficiency, alopecia (permanent), aplastic anemia (may be irreversible), azoospermia, bronchopulmonary dysplasia, capillary leak syndrome, cataracts (rare), cheilosis, cholestatic jaundice, corneal thinning, dry skin, endocardial fibrosis, erythema multiforme, esophageal varices, gynecomastia, hepatic dysfunction, hepatocellular atrophy, hyperuricemia, hyperuricosuria, interstitial pulmonary fibrosis, malignant tumors, myasthenia gravis, neutropenic fever, ocular (lens) changes, ovarian failure, pancytopenia, porphyria cutanea tarda, pulmonary fibrosis, radiation myelopathy, radiation recall (skin rash), sepsis, sterility, testicular atrophy, thrombotic microangiopathy (TMA), tumor lysis syndrome, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to busulfan or any component of the formulation; oral busulfan is contraindicated in patients without a definitive diagnosis of CML",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe bone marrow suppression is common; reduce dose or discontinue oral busulfan for unusual suppression; may require bone marrow biopsy.",
"     </b>",
"     May result in severe neutropenia, thrombocytopenia, anemia, bone marrow failure, and/or severe pancytopenia; pancytopenia may be prolonged (1 month up to 2 years) and may be reversible. Use with caution in patients with compromised bone marrow reserve (due to prior treatment or radiation therapy). Monitor closely for signs of infection (due to neutropenia) or bleeding (due to thrombocytopenia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular: Cardiac tamponade has been reported in children with thalassemia treated with high dose oral busulfan in combination with cyclophosphamide,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic sinusoidal obstruction syndrome: High busulfan area under the concentration versus time curve (AUC) values (&gt;1500 micromolar&bull;minute) are associated with increased risk of hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) due to conditioning for allogenic HSCT. Patients with a history of radiation therapy, prior chemotherapy (&ge;3 cycles), or prior stem cell transplantation are also at increased risk of hepatic SOS at recommended doses regimens. Oral busulfan doses above 16 mg/kg (based on IBW) and concurrent use with alkylating agents may also increase the risk for hepatic SOS. Monitor liver function tests periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian failure: Use has been associated with ovarian failure (including failure to achieve puberty) and amenorrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Bronchopulmonary dysplasia with pulmonary fibrosis (&ldquo;busulfan lung&rdquo;) is associated with busulfan; onset is delayed with symptoms occurring at an average of 4 years (range: 4 months to 10 years) after treatment; may be fatal. Symptoms generally include a slow onset of cough, dyspnea and fever (low-grade), although acute symptomatic onset may also occur. Diminished diffusion capacity and decreased pulmonary compliance have been noted with pulmonary function testing. Differential diagnosis should rule out opportunistic pulmonary infection or leukemic pulmonary infiltrates; may require lung biopsy. Discontinue busulfan if toxicity develops. Pulmonary toxicity may be additive if administered with other cytotoxic agents also associated with pulmonary toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Tumors and acute leukemias have been reported following use. Chromosomal alterations may also occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tissue dysplasia: Cellular dysplasia in many organs has been observed (in addition to lung dysplasia); giant hyperchromatic nuclei have been noted in adrenal glands, liver, lymph nodes, pancreas, thyroid, and bone marrow. May obscure routine diagnostic cytologic exams (eg, cervical  smear).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Seizures have been reported with busulfan; use with caution in patients predisposed to seizures, with a history of seizures or head trauma. When using as a conditioning regimen for transplant, initiate prophylactic anticonvulsant therapy (eg, phenytoin) prior to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticonvulsants: Phenytoin increases busulfan clearance by &ge;15%; busulfan kinetics and dosing recommendations for high-dose HSCT conditioning were studied with concomitant phenytoin. If alternate anticonvulsants are used, busulfan clearance may be decreased and dosing should be monitored accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dimethylacetamide (DMA): The solvent in I.V. busulfan, DMA, may impair fertility. DMA may also be associated with hepatotoxicity, hallucinations, somnolence, lethargy, and confusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. For the I.V. formulation, should be experienced in management of hematopoietic stem cell transplantation and management of patients with severe pancytopenia. According to the manufacturer, oral busulfan should not be used until CML diagnosis has been established.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: Busulfan may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Busulfan. Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol due to GI irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: No clear or firm data on the effect of food on busulfan bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease busulfan levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3880598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. The solvent in I.V. busulfan, DMA, is also associated with teratogenic effects and may impair fertility. Women of childbearing potential should avoid pregnancy while receiving busulfan treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5355759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Busulfex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/mL (10 mL): $1519.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Myleran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (25): $160.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count (weekly for palliative treatment; daily until engraftment for HSCT); liver function tests (evaluate transaminases, alkaline phosphatase, and bilirubin daily for at least 28 days post transplant). If conducting therapeutic drug monitoring for AUC calculations in HSCT, monitor blood samples at appropriate collections times (record collection times).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Busilvex (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Busulf (PK);",
"     </li>",
"     <li>",
"      Busulfex (AU, CL, HK, IL, KP, MY, SG, TH, TW);",
"     </li>",
"     <li>",
"      Mielucin (ES);",
"     </li>",
"     <li>",
"      Myleran (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, CZ, DE, EC, EE, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NZ, OM, PE, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Myran (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Busulfan is an alkylating agent which reacts with the N-7 position of guanosine and interferes with DNA replication and transcription of RNA. Busulfan has a more marked effect on myeloid cells than on lymphoid cells and is also very toxic to hematopoietic stem cells. Busulfan exhibits little immunosuppressive activity. Interferes with the normal function of DNA by alkylation and cross-linking the strands of DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1 L/kg; distributes into CSF with levels equal  to plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 32% to plasma proteins and 47% to red blood cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (may increase with multiple doses); glutathione conjugation followed by oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Children &ge;13 years and adults: 80% &plusmn; 20%; Children 1.5-6 years: 68% &plusmn; 31%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~1 hour; I.V.: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (25% to 60% predominantly as metabolites; &lt;2% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JE, Appelbaum FR, Schoch G, et al, &ldquo;Allogeneic Marrow Transplantation for Myelodysplastic Syndrome With Advanced Disease Morphology: A Phase II Study of Busulfan, Cyclophosphamide, and Total Body-Irradiation and Analysis of Prognostic Factors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(1):220-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/8558201/pubmed\" id=\"8558201\" target=\"_blank\">",
"        8558201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Booth BP, Rahman A, Dagher R, et al, &ldquo;Population Pharmacokinetic-Based Dosing of Intravenous Busulfan in Pediatric Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(1):101-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/17192508/pubmed\" id=\"17192508\" target=\"_blank\">",
"        17192508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassileth PA, Andersen J, Lazarus HM, et al, &ldquo;Autologous Bone Marrow Transplant in Acute Myeloid Leukemia in First Remission,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(2):314-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/8426209/pubmed\" id=\"8426209\" target=\"_blank\">",
"        8426209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassileth PA, Harrington DP, Appelbaum FR, et al, &ldquo;Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(23):1649-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/9834301/pubmed\" id=\"9834301\" target=\"_blank\">",
"        9834301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fabris F and Randi ML, &ldquo;Essential Thrombocythemia: Past and Present,&rdquo;",
"      <i>",
"       Intern Emerg Med",
"      </i>",
"      , 2009, 4(5):381-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/19636672/pubmed\" id=\"19636672\" target=\"_blank\">",
"        19636672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fermand JP, Katsahian S, Divine M, et al, &ldquo;High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(36):9227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/16275936/pubmed\" id=\"16275936\" target=\"_blank\">",
"        16275936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho VT, Aldridge J, Kim HT, et al, Comparison of Tacrolimus and Sirolimus (Tac/Sir) Versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-Versus-Host Disease Prophylaxis After Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(7):844-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/19539216/pubmed\" id=\"19539216\" target=\"_blank\">",
"        19539216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pulsipher MA, Boucher KM, Wall D, et al, &ldquo;Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(7):1429-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/19528536/pubmed\" id=\"19528536\" target=\"_blank\">",
"        19528536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Radich JP, Gooley T, Bensinger W, et al, &ldquo;HLA-Matched Related Hematopoietic Cell Transplantation for Chronic-Phase CML Using a Targeted Busulfan and Cyclophosphamide Preparative Regimen,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(1):31-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/12595317/pubmed\" id=\"12595317\" target=\"_blank\">",
"        12595317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regazzi MB, Locatelli F, Buggia I, et al, &ldquo;Disposition of High-Dose Busulfan in Pediatric Patients Undergoing Bone Marrow Transplantation,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(1):45-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/8330465/pubmed\" id=\"8330465\" target=\"_blank\">",
"        8330465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seddon BM, Cassoni AM, Galloway MJ, et al, &ldquo;Fatal Radiation Myelopathy After High-Dose Busulfan and Melphalan Chemotherapy and Radiotherapy for Ewing&rsquo;s Sarcoma: A Review of the Literature and Implications for Practice,&rdquo;",
"      <i>",
"       Clin Oncol (R Coll Radiol)",
"      </i>",
"      , 2005, 17(5):385-90.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw PJ, Nath C, Berry A, et al, &ldquo;Busulphan Given as Four Single Daily Doses of 150 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      Is Safe and Effective in Children of All Ages,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2004, 34(3):197-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/15195074/pubmed\" id=\"15195074\" target=\"_blank\">",
"        15195074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soci&eacute; G, Clift RA, Blaise D, et al, &ldquo;Busulfan Plus Cyclophosphamide Compared With Total-Body Irradiation Plus Cyclophosphamide Before Marrow Transplantation for Myeloid Leukemia: Long-Term Follow-Up of 4 Randomized Studies,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 98(13):3569-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/11739158/pubmed\" id=\"11739158\" target=\"_blank\">",
"        11739158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tefferi A, &ldquo;Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia Vera and Essential Thrombocythemia: 2011 Update on Diagnosis, Risk-Stratification, and Management,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2011, 86(3):292-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/21351120/pubmed\" id=\"21351120\" target=\"_blank\">",
"        21351120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tosti A, Piraccini BM, Vincenzi C, et al, &ldquo;Permanent Alopecia After Busulfan Chemotherapy,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2005, 152(5):1056-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/15888171/pubmed\" id=\"15888171\" target=\"_blank\">",
"        15888171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vassal G, Gouyette A, Hartmann O, et al, &ldquo;Pharmacokinetics of High-Dose Busulfan in Children,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1989, 24(6):386-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/10/10408/abstract-text/2791192/pubmed\" id=\"2791192\" target=\"_blank\">",
"        2791192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9173 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10408=[""].join("\n");
var outline_f10_10_10408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708634\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143389\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143390\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143435\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143394\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143415\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143395\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526939\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5526940\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143366\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143351\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143370\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143441\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143369\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143431\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143443\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143433\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143373\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143355\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143428\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143360\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143386\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143362\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3880598\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143404\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5355759\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143375\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143364\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143376\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143354\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143372\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9173\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9173|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/32/36357?source=related_link\">",
"      Busulfan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7479?source=related_link\">",
"      Busulfan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_10_10409="Bookwalter retractor A";
var content_f10_10_10409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59242%7ESURG%2F79154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59242%7ESURG%2F79154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Bookwalter retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bookwalter retractor and accessory retractors in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Bookwalter retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The retractor is positioned in the abdomen (A-C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10409=[""].join("\n");
var outline_f10_10_10409=null;
var title_f10_10_10410="Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis";
var content_f10_10_10410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10410/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10410/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/10/10410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/10/10410/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/10/10410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the late 1990s, the success of biologic agents in the treatment of rheumatoid arthritis (RA) has dramatically altered the approach to treating this disease and a variety of other inflammatory illnesses. Four biologic approaches have achieved major impact in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor necrosis factor (TNF)-alpha inhibition",
"     </li>",
"     <li>",
"      B-cell depletion",
"     </li>",
"     <li>",
"      Disruption of T-cell costimulation",
"     </li>",
"     <li>",
"      Interleukin (IL)-1 and IL-6 inhibition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major clinical trials of TNF inhibitors in RA will be reviewed here. General approaches to the therapy of RA and the major clinical trials of biologic agents other than TNF inhibitors and of non-biologic disease-modifying antirheumatic drugs (DMARDs) are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link\">",
"     \"T cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the trials included in this review were randomized, double-blind, placebo-controlled investigations. The focus in this review is on the clinical trials that were instrumental in defining the clinical roles of these biologic agents. For each trial, the following features are described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trial name &mdash; Each trial is listed by its acronym, the title of the paper in which the primary results were published, or both.",
"     </li>",
"     <li>",
"      Design &mdash; The duration of the trial, the number of patients studied, and the specific treatment groups are outlined.",
"     </li>",
"     <li>",
"      Patient population &mdash; The entry criteria are summarized, and the type of background therapy permitted is indicated.",
"     </li>",
"     <li>",
"      Primary outcome measures &mdash; The outcome measures specified in advance by the investigators are listed.",
"     </li>",
"     <li>",
"      Important secondary outcome measures &mdash; Other outcome measures essential to understanding the full impact of the intervention and the context of the trial are mentioned.",
"     </li>",
"     <li>",
"      Major results &mdash; The main efficacy results are reviewed. Important adverse effects are also mentioned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unless otherwise specified, all of the trials outlined below permitted patients to continue to use their baseline nonsteroidal antiinflammatory agents and stable doses of up to 9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TUMOR NECROSIS FACTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five inhibitors of tumor necrosis factor (TNF)-alpha are available for clinical use:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    . All TNF inhibitors are more effective when employed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    than when they are used as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1 (TNFR:Fc). Etanercept is administered by subcutaneous injection once or twice weekly. A number of major randomized clinical trials of etanercept have been conducted in RA.",
"   </p>",
"   <p>",
"    Trial name &mdash; Treatment of RA with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Three-month trial involving 180 patients, assigned to one of four treatment groups: either placebo or one of three doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      twice weekly. The etanercept doses were 0.25, 2, or 16",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      Patient population &mdash; RA patients refractory to at least one DMARD",
"     </li>",
"     <li>",
"      Primary outcomes &mdash; Changes in the number of swollen and tender joints between entry and the end of month three",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; The ACR20 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), ACR50, and adverse events were the major secondary outcomes.",
"     </li>",
"     <li>",
"      Major results &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      was associated with significant, dose-related reductions in disease activity. Seventy-five percent of patients assigned to the highest etanercept dose achieved ACR20 responses, compared with 14 percent in the placebo group.",
"      <br/>",
"      <br/>",
"      The mean percent reduction in the number of tender or swollen joints was 61 percent, compared with 25 percent in the placebo group. No dose-limiting adverse effects were observed, and no patients developed antibodies to etanercept.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    therapy in RA: A randomized, controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/4\">",
"     4",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Six-month trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      involving 234 patients, assigned to one of three treatment groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      25 mg twice weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      10 mg twice weekly",
"     </li>",
"     <li>",
"      Placebo twice weekly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; RA patients in ACR functional class I, II, or III [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/5\">",
"       5",
"      </a>",
"      ]. All patients had failed at least one but not more than four DMARDs. In addition, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least 10 swollen joints",
"     </li>",
"     <li>",
"      At least 12 tender joints",
"     </li>",
"     <li>",
"      An erythrocyte sedimentation rate &gt;27",
"      <span class=\"nowrap\">",
"       mm/hour,",
"      </span>",
"      a serum C-reactive protein level &gt;1.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      or at least 45 minutes of morning stiffness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR20 and ACR50 at three and six months (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR70 at three and six months, the number of swollen or tender joints, and quality of life",
"     </li>",
"     <li>",
"      Major results &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      significantly reduced disease activity and other outcome measures in a dose-related fashion at both three and six months. At six months, in the 25 mg, 10 mg, and placebo groups, an ACR20 response was achieved by 59, 51, and 11 percent of patients, respectively. An ACR50 response was achieved by 40, 24, and 5 percent of the three groups, respectively, and an ACR70 response was achieved by 15, 9, and 1 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; A trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a TNF receptor: Fc fusion protein in patients with RA receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/6\">",
"     6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Twenty-four-week trial that involved 89 patients assigned either to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      25 mg twice weekly or to receive placebo added to MTX",
"     </li>",
"     <li>",
"      Patient population &mdash; The patients had persistently active RA despite stable MTX doses between 15 and 25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      for at least six months. In addition, the patients had active disease defined as swelling in at least six joints and tenderness in at least six joints.",
"     </li>",
"     <li>",
"      Primary outcome &mdash; ACR20 at 24 weeks (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR20 at 12 weeks; ACR50 and ACR70 at 12 and 24 weeks",
"     </li>",
"     <li>",
"      Major results &mdash; At 24 weeks, 71 percent of the patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      plus MTX and 27 percent of those receiving placebo plus MTX achieved ACR20 responses. Thirty-nine percent of patients receiving etanercept plus MTX versus 3 percent of those receiving placebo plus MTX met the ACR50 criteria at that time point. Patients receiving etanercept plus MTX had significantly better outcomes according to all measures of disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; A comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and MTX in patients with early RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Twelve-month trial of 632 patients with &ldquo;early RA&rdquo; (defined below), treated either with twice-weekly subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (10 or 25 mg) or with weekly oral MTX (mean, 19 mg per week) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/7\">",
"       7",
"      </a>",
"      ]. A study of longer follow-up provided data on these patients at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient population &mdash; The patients had had RA for no more than three years and had never been treated with MTX. In addition, patients were required to have all of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rheumatoid factor positivity",
"     </li>",
"     <li>",
"      At least three bone erosions evident on radiographs of hands, wrists, and feet",
"     </li>",
"     <li>",
"      At least 10 swollen joints",
"     </li>",
"     <li>",
"      At least 12 tender joints",
"     </li>",
"     <li>",
"      An erythrocyte sedimentation rate &gt;27",
"      <span class=\"nowrap\">",
"       mm/hour,",
"      </span>",
"      a serum C-reactive protein level &gt;1.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      or at least 45 minutes of morning stiffness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; This trial used a new outcome measure for its primary outcome: the ACR-N [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/9\">",
"       9",
"      </a>",
"      ]. The ACR-N, which represents the overall response of each patient, was designated as the smallest degree of improvement from baseline in three criteria: the number of tender joints, the number of swollen joints, and the median of the five remaining measures of disease activity in the ACR response criteria (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ). A negative ACR-N indicates worsening of activity from baseline. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link&amp;anchor=H7361109#H7361109\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'ACR response criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; Percentages of patients with ACR20, ACR50, and ACR70 responses (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ). A primary radiologic endpoint was also identified: change in Sharp scores over a period of 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/5,10-12\">",
"       5,10-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major results &mdash; Patients in the group assigned to receive 25 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      twice weekly had significantly greater areas under the curve for ACR-N at 3, 6, 9, and 12 months, indicating superior clinical responses. Patients treated with etanercept 25 mg group also had a more rapid rate of improvement and a higher likelihood of achieving ACR20, ACR50, and ACR70 responses than did those in the MTX group. The 10 mg etanercept dose was not superior to MTX in most outcome measures.",
"      <br/>",
"      <br/>",
"      The mean increase in the erosion score during the first six months was 0.3 in the group assigned to receive 25 mg of etanercept and 0.68 in the MTX group. The increases during the first 12 months were 0.47 and 1.03, respectively. Adverse events, including infections, were also fewer in the 25 mg etanercept group.",
"      <br/>",
"      <br/>",
"      Data from the two-year follow-up study indicated that etanercept as monotherapy was superior to MTX in the reduction of disease activity, in the arrest of structural damage, and in the prevention of disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; Comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    monotherapy with a combination of methotrexate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in active, early, moderate to severe rheumatoid arthritis (COMET) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/13\">",
"     13",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Twelve-month trial of 542 patients with early, moderate to severe RA, treated either with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone (titrated from 7.5 to a maximum of 20",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      mean 19.6 mg) or with methotrexate (same titration, mean 16.8",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      plus subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/week).",
"      </span>",
"     </li>",
"     <li>",
"      Patient population &mdash; The patients were 18 years of age or older and had not been previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , or another TNF antagonist or had not been treated in the four weeks before baseline visits with either glucocorticoid injections or other DMARDs. In addition, patients met the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Disease duration of 3 to 24 months",
"     </li>",
"     <li>",
"      Disease activity score in 28 joints (DAS28) of 3.2 or greater (mean 6.5) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link&amp;anchor=H7361046#H7361046\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'DAS28 score'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ESR &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or CRP &ge;20",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; Proportion of patients achieving remission (DAS28 &lt;2.6) at week 52 and the change in van der Heijde modified total Sharp score (mTSS: joint erosion score plus joint space narrowing score) from baseline to week 52 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/12,14-16\">",
"       12,14-16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; Proportion of patients achieving DAS44 remission (DAS44 &lt;1.6), ACR20, ACR50, and ACR70 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ); functional status (health assessment questionnaire disability index); and employment status (stopping working during the study) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link&amp;anchor=H7361081#H7361081\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Health Assessment Questionnaire (HAQ)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Major results &mdash; At one year of treatment, remission was achieved significantly more often in patients receiving the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (50 versus 28 percent with methotrexate alone). In addition, radiographic non-progression was significantly more frequent with combination therapy (80 versus 59 percent). The frequency of serious adverse events, 12 percent overall, was comparable in the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is a chimeric",
"    <span class=\"nowrap\">",
"     (human/murine)",
"    </span>",
"    IgG1 monoclonal antibody directed against TNF. Infliximab is administered via intravenous infusion, typically at intervals of six to eight weeks following two doses separated by two weeks.",
"   </p>",
"   <p>",
"    Several major clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Two trials summarize the clinical evidence for the efficacy of infliximab in RA well [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trial name &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    and MTX in the treatment of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/17\">",
"     17",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Fifty-four week study of 428 patients randomized into five treatment groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (n = 88)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight weeks plus MTX (n = 86)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks plus MTX (n = 86)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight weeks plus MTX (n = 87)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks plus MTX (n = 81)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients with active RA despite at least 12.5 mg of",
"      <span class=\"nowrap\">",
"       MTX/week.",
"      </span>",
"      Active RA was defined as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      At least six tender joints",
"     </li>",
"     <li>",
"      At least two of the following: an erythrocyte sedimentation rate &gt; 27",
"      <span class=\"nowrap\">",
"       mm/hour,",
"      </span>",
"      a serum C-reactive protein level &gt;1.9",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      or at least 45 minutes of morning stiffness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR20 response (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50 and ACR70 responses and the Health Assessment Questionnaire (HAQ) score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/21\">",
"       21",
"      </a>",
"      ]. The effect of therapy on articular damage was assessed on the basis of the van der Heijde modification of the Sharp scoring system [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/12,14-16\">",
"       12,14-16",
"      </a>",
"      ], using radiographs of the hands and feet.",
"     </li>",
"     <li>",
"      Major results &mdash; The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and MTX was tolerated well and resulted in clinical responses in 52 percent of patients treated with both infliximab and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , compared with 17 percent of those treated with MTX alone. The symptoms and signs of RA decreased more in all of the infliximab groups as judged by ACR20, ACR50, and ACR70 responses compared with the group that received MTX alone.",
"      <br/>",
"      <br/>",
"      The improvement in HAQ scores was also significantly better with infliximab plus MTX than with MTX alone. Radiographic evidence of joint damage increased in the group given MTX but not in the groups given infliximab and MTX (mean change in radiographic score, 7 versus 0.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; Combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and MTX therapy for early RA (Active-Controlled Study of Patients Receiving Infliximab for the Treatment of RA of Early Onset, ASPIRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/20\">",
"     20",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Fifty-four-week trial involving 1049 patients randomized into three different treatment groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo plus MTX (20",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      (n = 298)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight weeks plus MTX (n = 373)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks plus MTX (n = 378)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Investigational infusions were administered at weeks zero, two, and six and then every eight weeks through week 46.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients with RA for longer than three months but less than three years who had never been treated with MTX. All patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least 10 swollen joints",
"     </li>",
"     <li>",
"      At least 12 tender joints",
"     </li>",
"     <li>",
"      One or more of the following: rheumatoid factor positivity, radiographic erosions of the hands or feet, or a serum C-reactive protein level &gt;1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; The percentage of ACR improvement (ACR-N) from baseline to week 54 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/7,9\">",
"       7,9",
"      </a>",
"      ]. As noted above, the ACR-N is defined as the minimum of the following three items:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The percentage change from baseline in the number of tender joints",
"     </li>",
"     <li>",
"      The percentage change from baseline in the number of swollen joints",
"     </li>",
"     <li>",
"      The median of the percentage change from baseline for the patient&rsquo;s global assessment, clinician&rsquo;s global assessment, pain, disability, and serum levels of C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A negative ACR-N indicates worsening of activity from baseline.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important secondary outcomes &mdash; ACR20 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), ACR50, ACR70, ACR90, HAQ score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/21,22\">",
"       21,22",
"      </a>",
"      ], and the Disease Activity Score in 28 joints (DAS28) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/23,24\">",
"       23,24",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link&amp;anchor=H7361046#H7361046\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'DAS28 score'",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      A major clinical response was defined as an ACR70 for six consecutive months.",
"      <br/>",
"      <br/>",
"      Radiologic outcomes were assessed using the van der Heijde modification of the total Sharp score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major results &mdash; The median percentage improvement in ACR-N was higher in the 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      groups compared with the MTX alone group (47 percent versus 39 percent versus 26 percent, respectively). However, only 17 percent, 12 percent, and 8 percent of patients in the three groups, respectively, achieved ACR70 responses for six consecutive months.",
"      <br/>",
"      <br/>",
"      Patients in the 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infliximab groups also showed less radiographic progression, measured by change in total Sharp score, than those receiving MTX alone: 0.4",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      5.8 and 0.5",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      5.6 versus 3.7",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      9.6, respectively. This difference could not be attributed entirely to greater reduction in disease activity, as less radiographic worsening was seen with infliximab treatment at each level of disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Physical function as measured by the HAQ score improved significantly more in the MTX 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infliximab and in the MTX 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infliximab groups than in the MTX placebo group.",
"      <br/>",
"      <br/>",
"      Infliximab therapy was associated with a significantly higher incidence of serious adverse events (5 versus 2 percent) and serious infections (2 versus 0 percent), especially community-acquired pneumonia (19 cases versus 0) and tuberculosis (four cases versus none).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    is a fully humanized IgG1 monoclonal antibody that inhibits TNF. Adalimumab is administered every two weeks by subcutaneous injection.",
"   </p>",
"   <p>",
"    Trial name &mdash; The ARMADA trial: A fully human anti-tumor necrosis factor-alpha monoclonal antibody for the treatment of RA in patients taking concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/26\">",
"     26",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Twenty-four week trial involving 271 patients assigned to receive MTX (20",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      plus either placebo or 20 mg, 40 mg, or 80 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      every other week",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients with RA who had been on a stable dose of MTX (between 12.5 and 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      for at least six months and who failed treatment with at least one but not more than four DMARDs, excluding MTX. In addition, all patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      At least nine tender joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR20 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50, ACR70, HAQ score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/21,22\">",
"       21,22",
"      </a>",
"      ], and serum C-reactive protein level",
"     </li>",
"     <li>",
"      Major results &mdash; An ACR20 response at week 24 was achieved by a significantly greater proportion of patients in all three",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      groups compared with MTX and placebo (48, 67, and 66 percent in the 20, 40, and 80 mg groups, respectively, compared with 15 percent in the",
"      <span class=\"nowrap\">",
"       MTX/placebo",
"      </span>",
"      group).",
"      <br/>",
"      <br/>",
"      The ACR50 response rates in the adalimumab groups (32, 55, and 43 percent, respectively) were significantly greater than in the",
"      <span class=\"nowrap\">",
"       MTX/placebo",
"      </span>",
"      group (8 percent). The 40 mg adalimumab group appeared to fare better than the 80 mg group, but the comparisons were not statistically significant. Twenty-seven percent of patients in the 40 mg group and 19 percent of those in the 80 mg group achieved ACR70 responses, compared with only 5 percent of the group treated with",
"      <span class=\"nowrap\">",
"       MTX/placebo.",
"       <br/>",
"       <br/>",
"       A",
"      </span>",
"      majority of patients in the adalimumab groups achieved ACR20 responses by the end of week one. Adverse events were not different among the four groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; Radiographic, clinical, and functional outcomes of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (a human anti-tumor necrosis factor monoclonal antibody) in patients with active RA receiving concomitant MTX therapy: a randomized, placebo-controlled, 52-week trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/27\">",
"     27",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; A 52-week trial involving 619 patients with active RA despite MTX who were randomized the one of three groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo plus MTX (20",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      (n = 200)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      20 mg every other week plus MTX (n = 212)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      40 mg every other week plus MTX (n = 207)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients with RA who had been on MTX for at least three months and on a stable dose (between 12.5 and 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      for at least one month. In addition, all patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      At least nine tender joints",
"     </li>",
"     <li>",
"      Either rheumatoid factor positivity or at least one joint erosion evident on radiographs of the hands and feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; Three primary outcome measures were identified:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inhibition of structural joint damage at week 52, assessed by a modified Sharp score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/5,10,11\">",
"       5,10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The ACR20 at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Physical function as measure by the disability index of the HAQ (the HAQ-DI) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important secondary outcomes &mdash; ACR50 and ACR70",
"     </li>",
"     <li>",
"      Major results &mdash; At week 52, there was less radiographic progression in the patients receiving either 40",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      or 20",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      as compared with",
"      <span class=\"nowrap\">",
"       MTX/placebo",
"      </span>",
"      (mean change 0.1, 0.8, and 2.7, respectively).",
"      <br/>",
"      <br/>",
"      At week 24, ACR20 responses were achieved by 63 and 61 percent of patients in the adalimumab groups, compared with 30 percent of patients in the",
"      <span class=\"nowrap\">",
"       MTX/placebo",
"      </span>",
"      group. These responses were maintained at 52 weeks. At week 52, the HAQ-DI scores demonstrated statistically significant improvement in the adalimumab groups compared with",
"      <span class=\"nowrap\">",
"       MTX/placebo.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      proportion of patients reporting serious infections was higher among patients receiving adalimumab (4 percent) than in the",
"      <span class=\"nowrap\">",
"       MTX/placebo",
"      </span>",
"      group (0.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/28\">",
"     28",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Two-year trial of 799 patients randomized to three groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo plus MTX 20",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      (n = 268)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      40 mg every other week alone (n = 274)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      40 mg every other week plus MTX (n = 257)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients with aggressive RA of less than three years&rsquo; duration who had not received MTX treatment previously. The patients&rsquo; RA was considered aggressive because they had at least one joint erosion. All patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least eight swollen joints",
"     </li>",
"     <li>",
"      At least ten tender joints",
"     </li>",
"     <li>",
"      An erythrocyte sedimentation rate &gt;27",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or a serum C-reactive protein level &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Rheumatoid factor positivity or at least one joint erosion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; Co-primary end points at year one were the ACR50 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ) and the mean change from baseline in the modified total Sharp score [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR20, ACR70, and ACR90. A major clinical response was defined as an ACR70 for six consecutive months.",
"     </li>",
"     <li>",
"      Major results &mdash; Combination therapy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      and MTX was superior to both MTX alone and adalimumab alone in all outcomes measured. At year one, 62 percent of patients receiving combination therapy exhibited an ACR50 response, compared with 46 and 41 percent of those who received MTX or adalimumab monotherapy. Similar superiority of combination therapy was seen in ACR20, ACR70, and ACR90 response rates at one and two years.",
"      <br/>",
"      <br/>",
"      There was significantly less radiographic progression among patients in the combination treatment arm at both year one and year two (1.3 and 1.9 Sharp units, respectively) than in patients in the MTX arm (5.7 and 10.4 Sharp units) or in the adalimumab arm (3.0 and 5.5 Sharp units).",
"      <br/>",
"      <br/>",
"      After two years of treatment, 49 percent of patients receiving combination therapy had achieved disease remission as indicated by a DAS28 score of less than 2.6, and 49 percent of those in the combination arm were categorized as having achieved major clinical responses as defined above. Both of these rates were approximately twice those found among patients receiving either monotherapy. The adverse event profiles were comparable in all three groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Golimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity. It is usually administered once monthly by subcutaneous injection but has also been studied using less frequent intravenous infusions.",
"   </p>",
"   <p>",
"    Trial name &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    in patients with active rheumatoid arthritis despite treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/30\">",
"     30",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; One-year trial involving 172 patients on a stable dose of MTX (&ge;10 mg weekly) who were randomly assigned to receive 50 or 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      every two or four weeks or to receive placebo. At week 20, the dosing interval for patients receiving golimumab every two weeks was increased to every four weeks, and patients on placebo were begun on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      infusions (3",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      Infliximab treatment was begun with infusions at weeks 20, 22, and 28 followed by maintenance therapy every eight weeks. Patients on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) or a glucocorticoid dose equivalent to &le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were allowed to continue these medications.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients with active RA for at least three months before screening, despite treatment with MTX (&ge;10",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      for three or more months and use of a stable dose for four or more weeks before receiving study drug. At study entry, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      At least six tender joints",
"     </li>",
"     <li>",
"      At least two of the following: C-reactive protein (CRP) &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      erythrocyte sedimentation rate (ESR) &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour,",
"      </span>",
"      and morning stiffness &ge;30 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR20 at week 16 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; DAS28 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/23,24\">",
"       23,24",
"      </a>",
"      ] and ACR-N index of improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/9\">",
"       9",
"      </a>",
"      ] at week 16; ACR20, ACR50, and ACR70 through week 52 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Major results &mdash; An ACR20 response at week 16 was achieved by a significantly greater proportion of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      plus MTX groups combined than in the placebo plus MTX group (61 versus 37 percent).",
"      <br/>",
"      <br/>",
"      Significantly greater proportions of patients in the golimumab groups achieved ACR50 and ACR70 responses at 16 weeks (30.7 versus 5.7 and 12.4 versus 0 percent, respectively). The ACR-N was significantly higher in the golimumab groups (23.5 versus -2.4). The reduction in the DAS28 in the golimumab groups was significantly greater when calculated using either CRP or ESR (-1.8 versus -0.9 and -2.1 versus -1.0, respectively).",
"      <br/>",
"      <br/>",
"      Serious adverse events through week 20 were reported in 9 percent of patients in the golimumab groups and in 6 percent of the placebo-treated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The GO-FORWARD study:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    , a human antibody to TNF-alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/31\">",
"     31",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; A 52-week randomized trial with an open-label extension up to five years involving 444 patients on a stable dose of MTX (&ge;15 to &le;25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      (100 or 50 mg every four weeks) plus either MTX or placebo capsules or to MTX plus placebo injections. Patients on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) or a glucocorticoid dose equivalent to &le;10 mg daily of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were allowed to continue these medications.",
"      <br/>",
"      <br/>",
"      At week 16, all patients with &lt;20 percent improvement in both tender and swollen joint counts, except those on golimumab 100 mg plus MTX, had blinded adjustment of medication dosing. For eligible patients receiving golimumab 50 mg plus MTX, golimumab was increased to 100 mg every four weeks, and MTX was continued. For eligible patients receiving golimumab plus placebo, the stable MTX dose taken by the patient prior to screening was resumed, and golimumab was continued. For eligible patients on MTX alone, golimumab 50 mg every four weeks was started, and MTX was continued.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients who had active RA and who were on MTX (&ge;15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      for at least three months before screening. Patients were on a stable MTX dose (15 to 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      during the four-week period immediately preceding screening. At study entry, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least four swollen joints",
"     </li>",
"     <li>",
"      At least four tender joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients had at least two of the following:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CRP &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or ESR &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"     </li>",
"     <li>",
"      Morning stiffness &ge; 30 minutes",
"     </li>",
"     <li>",
"      Bone erosion by radiograph or magnetic resonance imaging",
"     </li>",
"     <li>",
"      Positive anticyclic citrullinated peptide antibody or rheumatoid factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; ACR20 at week 14 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ) and Health Assessment Questionnaire disability index (HAQ-DI) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR20 at week 24, ACR50 and ACR70 at weeks 14 and 24, and DAS28 remission",
"     </li>",
"     <li>",
"      Major results &mdash; An ACR20 response at week 14 was achieved significantly more often in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      (100 or 50 mg) plus MTX compared with golimumab alone or MTX alone (56 and 55 percent versus 44 and 33 percent, respectively). Similar significant differences were seen in improvement in the HAQ-DI (-0.5 and -0.38 versus -0.13 versus -0.13).",
"      <br/>",
"      <br/>",
"      At week 24, after dose adjustments in eligible patients, higher rates of response were seen in golimumab plus MTX treated patients in the ACR20 (60 and 60 percent versus 35 and 28 percent), ACR50 (33 and 37 percent versus 20 versus 14 percent), and ACR70 (15 and 20 percent versus 11 and 5 percent, respectively). Differences between the groups receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone and the groups receiving both medications were statistically significant. A significantly higher rate of DAS28 remission was also observed (23 and 20 percent versus 12 and 6 percent). Benefit was sustained at week 52 (ACR20 of 58 and 64 percent versus 45 and 44 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Serious adverse events through week 16 in patients on golimumab (100 or 50 mg) plus MTX, golimumab plus placebo, or MTX plus placebo occurred in 9, 5.6, 3.8, and 2.3 percent of patients, respectively. Serious infections occurred in 5.6, 2.2, 0.8, and 0.8 percent of patients, respectively. Serious adverse events up to week 52 were attributed to the actual treatment received at the time of the event, rather than to the initial treatment to which the patient had been allocated, to account for the patients who underwent early escape at week 16 or crossover at week 24; they occurred in 18.3, 8, 12, and 4.5 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/32\">",
"       32",
"      </a>",
"      ]. Serious infections occurred in 7, 1.9, 3.8, and 0.8 percent of patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The GO-BEFORE study:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    before employing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as the first-line option in the treatment of rheumatoid arthritis of early onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/33\">",
"     33",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; A 52-week randomized trial with an open-label extension up to five years, involving 637 patients naive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX), biologic disease-modifying antirheumatic drugs (DMARDs), and cytotoxic agents, who were randomly assigned to one of four groups. In all groups, subcutaneous (SC) injections of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      or placebo were administered every four weeks, and capsules of MTX or placebo were given orally once weekly. MTX was started at 10",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      and the dose was escalated to 20",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      The four groups were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Group 1 &mdash; Placebo injection plus MTX capsules",
"     </li>",
"     <li>",
"      Group 2 &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      (100 mg) injection plus placebo capsules",
"     </li>",
"     <li>",
"      Group 3 &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      (50 mg) injection plus MTX capsules",
"     </li>",
"     <li>",
"      Group 4 &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      (100 mg) injection plus MTX capsules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) or a glucocorticoid dose equivalent to &le;10 mg daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    were allowed to continue these medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients with active RA for at least three months before start of study. At screening and baseline patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least four swollen joints",
"     </li>",
"     <li>",
"      At least four tender joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, at screening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    baseline patients had at least two of the following:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CRP &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      or ESR &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"     </li>",
"     <li>",
"      Morning stiffness &ge;30 minutes",
"     </li>",
"     <li>",
"      Bone erosion by radiograph or magnetic resonance imaging",
"     </li>",
"     <li>",
"      Positive anticyclic citrullinated peptide antibody or rheumatoid factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; The difference in the ACR50 response at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ) between groups 3 and 4 combined (combined group) versus group 1, and a pairwise comparison of group 3 or group 4 versus group 1.",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR20 at week 24 and DAS28 response at week 24",
"     </li>",
"     <li>",
"      Major results &mdash; An intent-to-treat analysis of the ACR50 response showed a trend toward a difference between the combined group (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      plus MTX) and group 1 (MTX alone) that did not achieve significance (38 versus 29 percent, p = 0.053). Group 2 (golimumab alone) was non-inferior to group 1 (MTX alone) at week 24 (33 versus 29 percent).",
"      <br/>",
"      <br/>",
"      The ACR20 was achieved significantly more often in the combined groups (golimumab plus MTX) compared with the MTX alone group (62 versus 49 percent), as was the DAS28 (using CRP level) good or moderate response (75 versus 61 percent).",
"      <br/>",
"      <br/>",
"      Serious adverse events occurred in groups 1 through 4 in 7, 3, 6, and 6 percent, respectively. Serious infections occurred in 2, 1, 1, and 4 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    , a new human anti-tumor necrosis factor-alpha antibody, administered intravenously in patients with active rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/34\">",
"     34",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; A 48-week trial involving 643 patients on a stable dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) (15 to 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      who were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      (either 2 or 4",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      administered intravenously every 12 weeks, with either MTX at their usual dose or placebo. At weeks 16 and 24, patients with less than 20 percent improvement in both the swollen and tender joint counts entered early escape and blinded dose regimen adjustment. The specific dose adjustment depended upon the specific preceding treatment. The maximal dose of golimumab was 4",
"      <span class=\"nowrap\">",
"       mg//kg,",
"      </span>",
"      and the maximal dose of MTX was the patient&rsquo;s stable prescreening MTX dose.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients with active RA for at least three months before screening, despite treatment with MTX (15 to 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      for three or more months and the use of a stable dose for four or more weeks before receiving study drug. At study entry, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least four swollen joints",
"     </li>",
"     <li>",
"      At least four tender joints",
"     </li>",
"     <li>",
"      At least two of the following: C-reactive protein (CRP) &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or erythrocyte sedimentation rate (ESR) &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour;",
"      </span>",
"      morning stiffness &ge;30 minutes; bone erosion by radiography or magnetic resonance imaging; or positive testing for anticyclic citrullinated peptide antibody or rheumatoid factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR50 at week 14 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50 at week 24, ACR20 at week 14 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), and DAS28-CRP [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Major results &mdash; An ACR50 response at week 14 was achieved by a greater proportion of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      plus MTX groups combined than in the placebo plus MTX group, but this difference was not significant (21 versus 13 percent, p = 0.051). The difference between these two groups was significant by week 24 (22 versus 9 percent). Differences between the groups receiving golimumab monotherapy and MTX monotherapy were not significant at either week 14 or 24.",
"      <br/>",
"      <br/>",
"      At week 48, the proportions of patients achieving ACR50 and ACR20 responses were highest among those who received golimumab 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      plus MTX (48 and 70 percent, respectively). A moderate or good DAS28-CRP response was achieved at week 14 significantly more often in patients receiving golimumab plus MTX or golimumab monotherapy, compared with MTX monotherapy (71 or 63 versus 44 percent) but remained significantly different at week 24 only for golimumab plus MTX (61, 43 and 40 percent, respectively). Patients receiving golimumab together with MTX had a lower rate of antibodies to golimumab than those treated without MTX (3 versus 9 percent).",
"      <br/>",
"      <br/>",
"      Serious adverse events through week 48 were seen more often in patients receiving golimumab (with or without MTX) compared with placebo plus MTX (10 versus 5 percent), including serious infections (4 versus 2 percent). The rate of any infection was also higher in patients who received golimumab (48 versus 41 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    may be effective in patients previously treated with one or more TNF inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7385?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\", section on 'MTX-golimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Certolizumab pegol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    (CZP) is a human anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-alpha. CZP is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be considered for maintenance therapy.",
"   </p>",
"   <p>",
"    Several major clinical trials of CZP have been performed in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. The efficacy and relative safety of CZP was shown in a systematic review and meta-analysis of trials involving over 2000 patients who received CZP after an inadequate response to nonbiologic disease-modifying antirheumatic drugs (DMARDs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), compared with placebo or placebo plus MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients receiving CZP (200 mg) were significantly more likely after six months of therapy to achieve an ACR50 response (risk ratio, RR, 6.0, 95% CI 3.8-9.4) with an absolute benefit of 29 percent (95% CI 25-34 percent). Serious adverse events were more frequent with CZP (odds ratio 2.0, 95% CI 1.2-3.3).",
"   </p>",
"   <p>",
"    As examples of the randomized trials, the first of two similar trials of CZP plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) is summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A trial of CZP monotherapy is also reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trial name &mdash; RAPID 1: RA prevention of structural damage 1 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/35\">",
"     35",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; One-year trial involving 982 patients on a stable dose of MTX (&ge;10 mg weekly) who were randomly assigned to CZP (400 mg at weeks 0, 2, and 4, followed by either 200 or 400 mg every two weeks) or placebo. Patients who did not achieve an ACR20 response at weeks 12 and 14 were withdrawn from the study at week 16. Patients on a stable dose of nonsteroidal antiinflammatory drugs or a glucocorticoid dose equivalent to &le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were allowed to continue these medications.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients with active RA despite treatment with MTX for six or more months who were on a stable MTX dose of &ge;10",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      for two or more months prior to baseline evaluation. Previous treatment with other DMARDs was permitted, with at least a 28-day washout period prior to baseline. For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , a six-month washout period was required unless",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      was used for drug elimination. At study entry, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least nine tender joints",
"     </li>",
"     <li>",
"      At least nine swollen joints",
"     </li>",
"     <li>",
"      An erythrocyte sedimentation rate &ge;30",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or a C-reactive protein &gt;15",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; ACR20 at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ) and change from baseline in modified total Sharp score (mTSS) at week 52 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50 and ACR70 at week 24, Health Assessment Questionnaire disability index (HAQ-DI) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/10/10410/abstract/22\">",
"       22",
"      </a>",
"      ] at weeks 24 and 52 and mean change from baseline in the mTSS at week 24.",
"     </li>",
"     <li>",
"      Major results &mdash; ACR20 responder rates at week 24 were significantly higher in patients who received CZP (200 or 400 mg) plus MTX than placebo plus MTX (59 and 61 versus 14 percent). At week 52, mean radiographic progression from baseline (change in mTSS) was significantly lower in the CZP treated patients (+0.4 and +0.2 versus +2.8).",
"      <br/>",
"      <br/>",
"      Efficacy was evident at week 1, by which time CZP-treated patients were more likely to have achieved an ACR20 response (23 and 22 versus 6 percent). At week 24, patients treated with CZP were more likely to achieve an ACR50 (37 and 40 versus 8 percent) or ACR70 (21 and 21 versus 3 percent).",
"      <br/>",
"      <br/>",
"      Significant improvement in physical function was also evident in the CZP-treated patients at week 1 (HAQ-DI mean change of -13.5 and -10.9 versus -2.4). This improvement was sustained through week 52 (-0.60 and -0.63 versus -0.18).",
"      <br/>",
"      <br/>",
"      The rates of serious adverse events and serious infections in the two CZP plus MTX groups and the placebo plus MTX patients were 15.2, 14.8, and 12.0 per 100 patient-years and 7.3, 5.3, and 2.2 per 100 patient-years, respectively. The most common serious infections were pneumonia, gastroenteritis, urinary tract infections, and tuberculosis. Tuberculosis was seen in five patients from Eastern Europe, but none from North America. These included three patients with negative chest radiographs and positive tuberculin skin tests who had received past BCG vaccination, and one individual who worked in a tuberculosis clinic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The FAST4WARD study: Efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (four weekly dose in rheumatoid arthritis)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Randomized 24-week trial of 220 patients allocated to receive subcutaneous injections of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      (CZP, 400 mg every four weeks) or placebo. Patients on a stable dose of nonsteroidal antiinflammatory drugs or a glucocorticoid dose equivalent to &le;10 mg daily of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      were allowed to continue these medications.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients with RA for at least six months, who had failed at least one disease modifying antirheumatic drug (DMARD) due to lack of efficacy or intolerance. Patients were excluded if they had previously received a TNF-alpha inhibitor. Prior to receiving the first dose of study drug, patients were not allowed to have received a biologic DMARD within six months, any DMARD for the greater of 28 days or five half lives of the drug, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      administration and a further 28 day washout.",
"      <br/>",
"      <br/>",
"      At study entry, patients had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least nine swollen joints",
"     </li>",
"     <li>",
"      At least nine tender joints",
"     </li>",
"     <li>",
"      At least one of the following: C-reactive protein (CRP) &ge; 10",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      erythrocyte sedimentation rate (ESR) &ge; 28",
"      <span class=\"nowrap\">",
"       mm/hour,",
"      </span>",
"      and morning stiffness &ge;45 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; ACR20 response at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50 and ACR70 at week 24, HAQ-DI, patient reported pain, and health-related quality of life",
"     </li>",
"     <li>",
"      Major results &mdash; The proportion of patients achieving an ACR20 response was significantly greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      at week 24 (46 versus 9 percent with placebo). Significant differences for ACR20 responses between CZP and placebo were evident after one week of therapy. CZP-treated patients were more likely to achieve ACR50 and ACR70 responses at week 24 (23 versus 4 and 6 versus 0 percent, respectively). Improvements were seen in all components of the ACR core measures set.",
"      <br/>",
"      <br/>",
"      Physical function was significantly improved by week one (HAQ-DI of -0.23 versus +0.04) and through week 24 (-0.36 versus +0.13). A significant decrease in arthritis pain from baseline (by visual analog scale) was also noted at week one (-16.7 versus -5.2) and through week 24 (-20.6 versus +1.7). Significant improvements were also seen in disease activity heath-related quality of life and fatigue.",
"      <br/>",
"      <br/>",
"      Serious adverse events and serious infections in patients on CZP and those on placebo were seen in 7.2 versus 2.8 and 1.8 versus 0 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13023298\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of biologic agents that inhibit tumor necrosis factor (TNF) alpha are available for use in the treatment of rheumatoid arthritis (RA) and several other disorders. The medications all improve the signs and symptoms of rheumatoid arthritis and reduce joint damage. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Tumor necrosis factor inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      is a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1 (TNFR:Fc). Etanercept is administered by subcutaneous injection once or twice weekly. Etanercept has proven effective in RA when used together with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or as monotherapy as the initial disease-modifying antirheumatic drug (DMARD) or in patients who have not responded adequately to prior DMARD therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etanercept'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      is a chimeric",
"      <span class=\"nowrap\">",
"       (human/murine)",
"      </span>",
"      IgG1 monoclonal antibody directed against TNF. Infliximab is administered via intravenous infusion, typically at intervals of six to eight weeks following two doses separated by two weeks. It has proven effective when used together with MTX as the initial DMARD or in patients who have not responded adequately to prior DMARD therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infliximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      is a fully humanized IgG1 monoclonal antibody that inhibits TNF. Adalimumab is administered every two weeks by subcutaneous injection. It has proven effective in RA when used together with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or as monotherapy as the initial disease-modifying antirheumatic drug (DMARD) or in patients who have not responded adequately to prior DMARD therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adalimumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity. It is usually administered once monthly by subcutaneous injection, but has also been studied using less frequent intravenous infusions. It has proven effective in RA when used together with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or as monotherapy as the initial disease-modifying antirheumatic drug (DMARD) or in patients who have not responded adequately to prior DMARD therapy. In a randomized trial, golimumab was effective in some patients previously treated with one or more TNF inhibitors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Golimumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      (CZP) is a human anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-alpha. CZP is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be considered for maintenance therapy. It has proven effective when used as monotherapy or together with MTX in patients who have not responded adequately to prior DMARD therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Certolizumab pegol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/1\">",
"      Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/2\">",
"      Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/3\">",
"      Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/4\">",
"      Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/5\">",
"      Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/6\">",
"      Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/7\">",
"      Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/8\">",
"      Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/9\">",
"      Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005; 52:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/10\">",
"      Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/11\">",
"      Plant MJ, Saklatvala J, Borg AA, et al. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/12\">",
"      van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/13\">",
"      Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/14\">",
"      van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/15\">",
"      van der Heijde DM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996; 10:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/16\">",
"      Lassere M, Boers M, van der Heijde D, et al. Smallest detectable difference in radiological progression. J Rheumatol 1999; 26:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/17\">",
"      Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/18\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/19\">",
"      Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/20\">",
"      St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/21\">",
"      Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/22\">",
"      Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/23\">",
"      van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/24\">",
"      M&auml;kinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/25\">",
"      Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/26\">",
"      Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/27\">",
"      Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/28\">",
"      Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/29\">",
"      van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/30\">",
"      Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/31\">",
"      Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/32\">",
"      Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010; 69:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/33\">",
"      Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/34\">",
"      Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010; 62:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/35\">",
"      Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/36\">",
"      Smolen J, Landew&eacute; RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/37\">",
"      Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/38\">",
"      Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/10/10410/abstract/39\">",
"      Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011; :CD007649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7499 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10410=[""].join("\n");
var outline_f10_10_10410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13023298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TUMOR NECROSIS FACTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Golimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Certolizumab pegol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13023298\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/30/26091\" title=\"table 1\">",
"      ACR RA response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7385?source=related_link\">",
"      Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_10_10411="Nonasphyxial events and CP";
var content_f10_10_10411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria that suggest an intrapartum timing of an event that may be related to the development of cerebral palsy but is not specifically asphyxial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A sentinel hypoxic event occurring immediately before or during labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A sudden and sustained fetal bradycardia or absence of fetal heart rate variability in the presence of persistent late or variable decelerations. This usually occurs after a hypoxic sentinel event with a normal fetal heart rate pattern prior to the event.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apgar score of 0 to 3 after five minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset of multisystem involvement within 72 hours of birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early imaging studies showing evidence of an acute nonfocal cerebral abnormality",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Task force on neonatal encephalopathy and cerebral palsy, American College of Obstetricians and Gynecologists (ACOG). Neonatal Encephalopathy and Cerebral Palsy: Executive Summary. Obstet Gynecol 2004; 103:780.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10411=[""].join("\n");
var outline_f10_10_10411=null;
var title_f10_10_10412="Previous classification IIP";
var content_f10_10_10412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Previous classification of idiopathic interstitial pneumonias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Liebow and Carrington (1969)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Usual interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desquamative interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brochiolitis obliterans interstitial pneumonia and diffuse alveolar damage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoid interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giant cell interstitial pneumonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Katzenstein (1997)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Usual interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desquamative interstitial pneumonia/respiratory bronchiolitis interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonspecific interstitial pneumonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            M&uuml;ller and Colby (1997)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Usual interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desquamative interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brochiolitis obliterans organizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonspecific interstitial pneumonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10412=[""].join("\n");
var outline_f10_10_10412=null;
var title_f10_10_10413="Doses of IV antibiotics for bacterial arthritis in children";
var content_f10_10_10413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of parenteral antibiotics commonly used in the treatment of bacterial arthritis in infants and children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intravenous agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose for infants 1 week to 1 month of age and birthweight &gt;2 kg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose for children &gt;1 month of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        100 to 200 mg/kg per day divided in 4 doses",
"       </td>",
"       <td>",
"        200 to 400 mg/kg per day divided in 4 doses; maximum dose 6 to 12 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        100 mg/kg per day divided in 3 doses; maximum dose 4 to 6 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day divided in 3 doses",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day divided in 3 or 4 doses; maximum dose 8 to 10 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        150 mg/kg per day divided in 3 doses",
"       </td>",
"       <td>",
"        125 to 150 mg/kg per day divided in 3 doses; maximum daily dose 6 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        50 to 75 mg/kg per day in 1 dose",
"       </td>",
"       <td>",
"        80 to 100 mg/kg per day divided in 1 or 2 doses; maximum dose 4 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        20 to 30 mg/kg per day divided in 4 doses",
"       </td>",
"       <td>",
"        25 to 40 mg/kg per day divided in 3 or 4 doses; maximum daily dose 1.2 to 2.7 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daptomycin&bull;",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        6 to 10 mg/kg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        7.5 mg/kg per day divided in 3 doses",
"       </td>",
"       <td>",
"        7.5 mg/kg per day divided in 3 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Linezolid",
"       </td>",
"       <td rowspan=\"2\">",
"        30 mg/kg per day divided in 3 doses",
"       </td>",
"       <td>",
"        &lt;12 years: 30 mg/kg per day in 3 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;12 years: 20 mg/kg per day in 2 doses; maximum daily dose 1200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        100 to 140 mg/kg per day divided in 4 doses",
"       </td>",
"       <td>",
"        100 to 150 mg/kg per day divided in 4 doses; maximum dose 4 to 12 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"       </td>",
"       <td>",
"        100 to 200 mg/kg per day divided in 4 doses",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day divided in 4 to 6 doses; maximum dose 4 to 12 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin",
"       </td>",
"       <td>",
"        100,000 to 200,000 units/kg per day divided in 4 doses",
"       </td>",
"       <td>",
"        250,000 to 400,000 units/kg per day divided in 4 to 6 doses; maximum dose 24 million units per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        30 to 45 mg/kg per day divided in 3 or 4 doses",
"       </td>",
"       <td>",
"        40 to 60 mg/kg per day divided in 3 doses; maximum dose 2 to 4 g/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not available.",
"     <br>",
"      * See text for details regarding indications for particular drugs; recommended doses are for patients with normal renal function.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Daptomycin should not be used in children with concomitant pulmonary involvement. It is not approved for the treatment of septic arthritis in children; the appropriate dose has not been established.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        American Academy of Pediatrics. Antibacterial drugs for newborn infants: Dose and frequency of administration. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.745.",
"       </li>",
"       <li>",
"        American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.747.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10413=[""].join("\n");
var outline_f10_10_10413=null;
var title_f10_10_10414="Overview of prenatal CF screening";
var content_f10_10_10414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk that both partners carry a CFTR mutation and the risk they will have a child with CF based on their test results and race/ethnicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Carrier frequency in population and proportion of CF identified by carrier screening (23 mutation panel)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Results of partner screening",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        <p>",
"         Risk that both parents are carriers",
"        </p>",
"        <p>",
"         1 in",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        <p>",
"         Risk of child with CF",
"        </p>",
"        <p>",
"         1 in",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Not tested",
"       </td>",
"       <td class=\"subtitle2\">",
"        Negative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Ashkenazi Jewish (1/23.8, 94.04 percent)",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        570",
"       </td>",
"       <td>",
"        2270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        147,000",
"       </td>",
"       <td>",
"        490,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        9140",
"       </td>",
"       <td>",
"        36,600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        23.8",
"       </td>",
"       <td>",
"        95.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        384",
"       </td>",
"       <td>",
"        1540",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Non-Hispanic Caucasian (1/25.0, 88.29 percent)",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        625",
"       </td>",
"       <td>",
"        2500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        42,400",
"       </td>",
"       <td>",
"        170,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5150",
"       </td>",
"       <td>",
"        20,600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        206",
"       </td>",
"       <td>",
"        824",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        African American (1/61.4, 64.46 percent)",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3770",
"       </td>",
"       <td>",
"        15,100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        29,200",
"       </td>",
"       <td>",
"        117,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        10,500",
"       </td>",
"       <td>",
"        42,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        61.4",
"       </td>",
"       <td>",
"        246",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        684",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Hispanic Caucasian (1/58.2, 71.72 percent)",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3380",
"       </td>",
"       <td>",
"        13,500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        41,200",
"       </td>",
"       <td>",
"        165,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        11,800",
"       </td>",
"       <td>",
"        47,200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        58.1",
"       </td>",
"       <td>",
"        232",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        812",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Asian American (1/93.7, 48.93 percent)",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8780",
"       </td>",
"       <td>",
"        35,100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        33,500",
"       </td>",
"       <td>",
"        134,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        XX",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        17,100",
"       </td>",
"       <td>",
"        68,600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        93.7",
"       </td>",
"       <td>",
"        375",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        732",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     X: the result for one of the partners.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American College of Medical Genetics. Technical Standards and Guidelines for CFTR Mutation Testing. 2006 Edition. Available at: file://www.acmg.net/Pages/ACMG_Activities/stds-2002/cf.htm. Copyright &copy; 2006 American College of Medical Genetics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10414=[""].join("\n");
var outline_f10_10_10414=null;
var title_f10_10_10415="Autosomal recessive--pedigree";
var content_f10_10_10415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of an autosomal recessive pedigree",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autosomal recessive trait. Double line denotes consanguineous mating of first cousins. Features of autosomal recessive inheritance seen here include: absence of family history of disease in prior generations, 25 percent affected status rate among siblings of affected subject; history of consanguinity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_10_10415=[""].join("\n");
var outline_f10_10_10415=null;
